focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCLIN.L Share News (CLIN)

  • There is currently no data for CLIN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: Rockhopper rises as Navitas enters project

Wed, 08th Dec 2021 11:45

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

----------

AIM - WINNERS

----------

Rockhopper Exploration PLC, up 22% at 6.38 pence, 12-month range 4.50p-12.50p. The oil & gas exploration and production company says Navitas Petroleum LP is to enter its Sea Lion oil project in the Falkland Islands. Navitas replaces Harbour Energy PLC as Rockhopper's partner in the project.

----------

Equals Group PLC, up 12% at 70.40p, 12-month range 26.10p-73.00. The fintech payments firm says it has "significantly exceeded" its full-year expectations for both adjusted earnings and revenue. Group revenue for the year to date is GBP40.4 million, up 51% from GBP26.8 million for the same period in 2020. The strong revenue performance means increased gross profit and earnings, and Equals says it has exceeded its own full-year profitability forecasts, but does not provide a figure.

----------

Clinigen Group PLC, up 10% at 901.00p, 12-month range 541.50p-912.00p. Shares hit 12-month high after the pharmaceuticals and services provider agrees to be taken private by European investment firm Triton Funds in a GBP1.2 billion deal. Under the terms, Clinigen shareholders will receive 883p a share in cash. This is a 41% premium to the ex-dividend closing share price on December 1, which was the last business day before takeover talks were first announced. Clinigen shareholders will also be entitled to receive the previously declared final dividend of 5.46p a share.

----------

AIM - LOSERS

----------

Byotrol PLC, down 16% at 4.22p, 12-month range 4.00p-7.70p. Shares in the antimicrobial technologies company hit fresh 12-month low after profit warning and says its first half performance was below expectations. For six months to September 30, swings to pretax loss of GBP141,000 from GBP1.0 million profit year before. "Whilst we expect to be both profitable and cash generative in the second half of the year, with these uncertainties it is difficult to predict the quantum at this juncture. At present we are expecting IP sales to offset the majority of the anticipated shortfall in profit on product sale, but projecting the timing of IP sales is even more uncertain, so we feel it prudent to now reduce market guidance for the current financial year," it says.

----------

By Arvind Bhunjun; arvindbhunjun@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
16 Sep 2021 09:53

LONDON BROKER RATINGS: Deutsche Bank cuts Unilever and Britvic to Hold

LONDON BROKER RATINGS: Deutsche Bank cuts Unilever and Britvic to Hold

Read more
9 Sep 2021 16:01

UK earnings, trading statements calendar - next 7 days

UK earnings, trading statements calendar - next 7 days

Read more
2 Sep 2021 14:28

Clinigen signs UK distribution deal for Paion hospital drugs

Clinigen signs UK distribution deal for Paion hospital drugs

Read more
1 Sep 2021 14:07

EXECUTIVE CHANGES: Next adds SEGRO CFO to board as non-exec director

EXECUTIVE CHANGES: Next adds SEGRO CFO to board as non-exec director

Read more
1 Sep 2021 09:12

Allen out, Schnee in as Cliningen board chairman

(Sharecast News) - Pharmaceutical products and services company Clinigen announced on Wednesday that non-executive director and chairman-designate Elmar Schnee was becoming chairman with immediate effect.

Read more
25 Aug 2021 20:39

EXECUTIVE CHANGES: Clinigen CFO to depart, replacement search underway

EXECUTIVE CHANGES: Clinigen CFO to depart, replacement search underway

Read more
25 Aug 2021 07:34

Clinigen CFO Nick Keher steps down

(Sharecast News) - Pharmaceutical group Clinigen said on Wednesday that chief financial officer Nick Keher has stepped down with immediate effect "to pursue other business interests".

Read more
5 Aug 2021 10:45

Clinigen inks partnership agreement with Eyevance Pharmaceuticals

(Sharecast News) - Pharmaceutical firm Clinigen said on Thursday that it has inked an exclusive partnership agreement with Eyevance Pharmaceuticals, a wholly-owned subsidiary of Santen Pharmaceutical.

Read more
5 Aug 2021 10:42

Clinigen partners with Eyevance to supply antifungal drug Natacyn

Clinigen partners with Eyevance to supply antifungal drug Natacyn

Read more
3 Aug 2021 15:29

EXECUTIVE CHANGES: Clinigen taps new chair; essensys hires from WeWork

EXECUTIVE CHANGES: Clinigen taps new chair; essensys hires from WeWork

Read more
21 Jul 2021 14:44

IN BRIEF: Clinigen to manage distribution of epilepsy drug Kigabeq

IN BRIEF: Clinigen to manage distribution of epilepsy drug Kigabeq

Read more
14 Jul 2021 13:23

Wednesday broker round-up

(Sharecast News) - Carnival: Berenberg upgrades to hold with a target price of 1,400p.

Read more
13 Jul 2021 10:43

Clinigen expects annual revenue rise in transitional year

Clinigen expects annual revenue rise in transitional year

Read more
13 Jul 2021 09:36

Clinigen ends year in line with expectations

(Sharecast News) - Pharmaceutical products and services company Clinigen updated the market on its just-ended financial year on Tuesday, saying net revenue was expected to be £455m, representing an increase of 12% on both a constant currency and organic basis.

Read more
11 Jul 2021 18:55

Sunday share tips: Clinigen, UK companies

(Sharecast News) - The Sunday Times's Sabah Meddings told readers to 'hold' shares of Clinigen amid some resurgent 'market chatter' regarding a possible bid emerging for the medicines supplier.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.